NCT07119710 Telehealth to Improve Quality of Life in Persons Living in Rural Texas
| NCT ID | NCT07119710 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Texas Tech University |
| Condition | Mental Health Issue |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-03-24 |
| Primary Completion | 2028-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2023-03-24 with a primary completion date of 2028-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overarching goal of this project is to evaluate a current evidence-based practice, Cognitive Behavioral Therapy, for mental health conditions against Cognitive Behavioral Therapy plus two check-in calls a week for adults living in rural Texas.
Eligibility Criteria
Inclusion Criteria: * family caregiver of person with all forms of dementia Exclusion Criteria: * not in another clinical intervention
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07119710 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 110 Years, studying Mental Health Issue. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07119710 currently recruiting?
Yes, NCT07119710 is actively recruiting participants. Contact the research team at jonsinge@ttu.edu for enrollment information.
Where is the NCT07119710 trial being conducted?
This trial is being conducted at Lubbock, United States.
Who is sponsoring the NCT07119710 clinical trial?
NCT07119710 is sponsored by Texas Tech University. The trial plans to enroll 60 participants.